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The cardiac Nav1.5 mediated sodium current (INa) generates the upstroke of the action 
potential in atrial and ventricular myocytes. Drugs that modulate this current can therefore 
be antiarrhythmic or proarrhythmic, which requires preclinical evaluation of their potential 
drug-induced inhibition or modulation of Nav1.5. Since Nav1.5 assembles with, and 
is modulated by, the auxiliary β1-subunit, this subunit can also affect the channel’s 
pharmacological response. To investigate this, the effect of known Nav1.5 inhibitors 
was compared between COS-7 cells expressing Nav1.5 or Nav1.5+β1 using whole-cell 
voltage clamp experiments. For the open state class Ia blockers ajmaline and quinidine, 
and class Ic drug flecainide, the affinity did not differ between both models. For class Ib 
drugs phenytoin and lidocaine, which are inactivated state blockers, the affinity decreased 
more than a twofold when β1 was present. Thus, β1 did not influence the affinity for the 
class Ia and Ic compounds but it did so for the class Ib drugs. Human stem cell-derived 
cardiomyocytes (hSC-CMs) are a promising translational cell source for in vitro models 
that express a representative repertoire of channels and auxiliary proteins, including β1. 
Therefore, we subsequently evaluated the same drugs for their response on the INa in 
hSC-CMs. Consequently, it was expected and confirmed that the drug response of INa in 
hSC-CMs compares best to INa expressed by Nav1.5+β1.
Keywords: arrhythmic, SCN5A, lidocaine, phenytoin, flecainide, quinidine, patch-clamp
INTRODUCTION
A major cause of cardiac liabilities is drug-induced arrhythmia by the modulation of different ion 
channels in the heart. One of the most important targets is the sodium current (INa) that generates 
the primary depolarizing power determining the upstroke of the action potential (AP) in human 
atria and ventricular myocytes. Effects on this ion channel should be scrutinized, as inhibition 
or modulation of it can cause severe adverse drug effects associated with arrhythmia (Lu et al., 
2010; Jung and Kwak, 2016). This liability is clearly demonstrated in, e.g., the Cardiac Arrythmia 
Suppression Trial (CAST) of the late eighties demonstrating the proarrhythmogenic complications 
associated with INa inhibitors (Cardiac Arrhythmia Suppression Trial (CAST) Investigators, 1989). 
Human (induced pluripotent) stem cell-derived cardiomyocytes (hSC-CMs), which express a 
repertoire of ion channel proteins including their auxiliary subunits, are a promising cell source 
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for human representative in vitro models for early cardiac 
proarrhythmia detection. Although limitations related to 
maturation of the currently available hSC-CMs may still give 
some concerns in predicting proarrhythmia, the expression of a 
repertoire of various ion channel related proteins can clearly be 
to their advantage over the study of drug effects in heterologous 
expression systems representing single ion channels.
The cardiac INa is mainly constituted by coassembly of the 
voltage-gated sodium Nav1.5 α-subunit, the channel forming 
protein that is expressed by the SCN5A gene, and auxiliary 
subunits in a noncovalent manner (Gellens et al., 1992; Isom et al., 
1994). It has been demonstrated that these auxiliary subunits can 
modulate the Nav1.5 channel properties, such as altering the 
current density and the kinetics of activation and/or inactivation 
(Abriel, 2010). The auxiliary β1-subunit is well documented to 
associate noncovalently with the Nav1.5 α-subunit (Zhu et al., 
2017), which upon association is known to increase the INa density 
by facilitating the integration of the Nav1.5 α-subunit into the cell 
membrane (Qu et al., 1995). The effects on the kinetics of Nav1.5 
are rather minor but they vary between reports, as reviewed by 
Baroni and Moran (2015). Since the modulating effect of β1 on 
the pharmacological response of Nav1.5 is less studied (Makielski 
et al., 1996), expression differences of this subunit in hSC-CMs and 
heterologous expression models could result in pharmacological 
differences between both systems. To address this, the effect of 
β1 on the pharmacological profile of Nav1.5 was first determined 
in a heterologous expression system and subsequently compared 
to the pharmacological effect of INa in Cor.4U hSC-CMs. These 
hSC-CMs are reported to at least express β1 thus potentially 
recapitulating the native INa of ventricular cardiomyocytes (Huo 
et al., 2017; Moreau et al., 2017).
Drugs that inhibit/modulate Nav1.5 have been classified in 
three classes (Ia, Ib and Ic) (Harrison, 1986). Whereas the mode 
of action of these drugs can differ, they are mostly following the 
modulated receptor hypothesis whereby the channel needs to be 
in a specific state to be affected by the drug (Hondeghem, 1987). 
This can lead to a use dependency for some drugs: the more the 
channel is activated, i.e., the more often it transitions from the 
closed to the open or inactivated state(s) and back, the stronger 
is the effect of the drug (Hille, 1977). In this study, five different 
drugs (selected to represent the three different classes) were 
evaluated for their effect on the INa with the aim to i) compare 
the affinity of INa inhibitors between hSC-CMs (Cor.4U) and 
Nav1.5 expressed in heterologous cell lines and ii) determine the 
contribution of the auxiliary β1 subunit in the pharmacological 
response of INa.
MATeRIAl AND MeTHODS
Cell Culture and Transient  
Transfection Protocol
COS-7 cells (CV-1 in Origin with SV40 genes) were selected as 
heterologous expression system because of the absence of reports 
on the expression of endogenous β1 and Nav channel subunits. 
Cells were cultured in 20-cm2 dishes with 5 ml of DMEM 
medium supplemented with 4.5 g/l D-Glucose + D-Glutamate, 
10% Foetal bovine serum, and 1% penicillin/streptomycin in a 
Galaxy B incubator (RS Biotech, Irvin, United Kingdom) under 
5% CO2 atmosphere at 37°C. All products were obtained from 
Gibco (Thermo Fisher, Waltham, Massachusetts, USA). COS-7 
cells were transiently transfected with 5 μg hSCN5A cDNA 
(cloned in a Pcl 398 vector) per 20 cm2 cell culture dishes or 
cotransfected in a 1:1 ratio with 5 µg hSCN5A and 5 µg hSCN1B 
(cloned in pRcCMV), using lipo2000 as transfection reagent 
(Invitrogen, Carlsbad, CA, USA). Transfection was performed on 
cells of 20-cm2 dishes in which the culture reached approximately 
70% confluency. 0.5 µg of the eGFP-expressing plasmid was 
cotransfected to visualize successfully transfected cells under 
an Eclipse TE2000-U inverted fluorescence microscope 
(Nikon instruments Europe, Amsterdam, Netherlands) during 
electrophysiological patch-clamp experiments. After 48-hour 
incubation of the cells in culture medium with transfection 
solution at 37°C, the cells were harvested by trypsinization and 
used for patch-clamp experiments.
hSC-CMs (Cor.4U cells) were purchased from Ncardia 
(Cologne, Germany) and delivered in liquid nitrogen frozen 
vials containing 250K (Ax-B-HC02-MPC) or 1M cells (Ax-B-
HC02-1M). hSC-CMs were seeded, following the provider’s 
protocols, on fibronectin coated glass coverslips and stored in 
a 24-well plate at 37°C and under 5% CO2 atmosphere with 1 
ml Cor.4U media without antibiotics per well. The fibronectin 
coating was done by adding 400 µl of a 10-µg/ml fibronectin 
solution, which was obtained by diluting a 1-mg/ml fibronectin 
stock in 0.05 M TBS (Tris-buffered saline) at pH 7.5 (Sigma-
Aldrich, St.Louis, Missouri, USA) in PBS with Ca2+ and Mg2+. 
For accurate voltage-clamp experiments, cells were seeded at low 
densities to obtain single isolated hSC-CMs on the cover slip. 
hSC-CMs were stored in an IGO150 cell life incubator (Waltham, 
Massachusetts, USA) under 5% CO2 atmosphere at 37°C. When 
the hSC-CM cells were frozen at Ncardia, they were at day 31 
postdifferentiation. After seeding, the hSC-CMs were cultured 
for another week before starting voltage-clamp experiments, 
giving them enough time to recover from thawing. Subsequently, 
electrophysiological experiments were performed within the 
following 2 weeks (i.e., day 38 to 52 postdifferentiation).
electrophysiology and Applied  
Pulse Protocols
Whole cell patch-clamp experiments were performed on hSC-
CMs and transient transfected COS-7 cells, at room temperature 
(21°C ± 1°C), using an Axopatch 200B amplifier (Axon CNS 
Molecular devices, San Jose, CA, USA). Current recordings were, 
after passing a 5- or 10-kHz low pass filter, sampled at 10 or 20 
kHz and digitized using a Digidata 1440A (Axon CNS Molecular 
devices). Applied voltage protocols and elicited current recordings 
were controlled and stored using the pClamp10 software (Axon 
CNS Molecular devices). Patch pipettes were pulled from 1.2-
mm quick-fill borosilicate glass capillaries (World Precision 
Instruments, Sarasota, FL, USA) with a horizontal P-2000 puller 
(Sutter Instrument Co., Novato, CA, USA) and subsequently heat 
polished. Pipette resistance varied between 1 and 1.5 MΩ for 
patching COS-7 cells and between 2 and 4 MΩ for hSC-CMs. The 
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shape of the pipettes for an improved sealing quality on hSC-CM 
was sharper, resulting in the slightly higher pipette resistance. The 
glass pipettes were backfilled with an intracellular solution (ICS) 
containing in mM: KCl 150, NaCl 5, CaCl2 2, MgCl2 5, EGTA 
5, HEPES 10, and adjusted to pH 7.2 with KOH. The cells were 
superfused continuously, at a rate of approximately 1 ml/min, with 
an extracellular solution (ECS) containing in mM: NaCl 150, KCl 
5.4, CaCl2 1.8, MgCl2 1, glucose 15, HEPES 15, Na-pyruvate 1, 
and adjusted to pH 7.4 with NaOH. These ICS and ECS solutions 
were used for measuring INa in both the heterologous COS-7 and 
hSC-CM cells. Because of its fast kinetics the INa could be well 
determined in hSC-CM without the need of selectively blocking 
other currents. However, to minimize the possible contribution 
of a small Ito K+ current, the INa drug response was determined 
at −10 mV to have minimal Ito activation (Cordeiro et al., 2013). 
The following drugs were dissolved in a 100% DMSO stock 
solution: flecainide (40 mM stock, reported pKa of 9.3), quinidine 
(40 mM stock, reported pKa of 8.56), lidocaine (200 mM stock, 
reported pKa between 7.6 and 8.0), phenytoin (200 mM stock, 
reported pKa of 8.33), and ajmaline (200 mM stock, reported 
pKa of 8.32). Test concentrations were made daily by diluting the 
stock solutions further and dissolving them in ECS, yielding for 
each drug concentration tested a final DMSO concentration of 
0.1%. Due to solubility, it was not possible to make a phenytoin 
concentration larger than 300 μM.
Four different voltage protocols were applied. The first 
(activation) protocol consisted out of 21 sweeps with each sweep 
composed of four different voltage steps. Starting from a holding 
potential of −90 mV, a fixed 80 ms conditioning prepulse to −130 
mV was applied followed by a 40-ms depolarizing step that varied 
between +80 and –130 mV. After the depolarizing step, the cell 
was always clamped back to −90 mV. Intersweep interval was set at 
8 s and every new sweep was preceded by a pulse P/-6 subtraction 
protocol starting from −90 mV holding. This P/-6 protocol 
allowed subtracting the capacitive currents in the recordings and 
consequently corrected for leak (Supplemental Figure 1).
The second (inactivation) protocol was used to determine the 
amount of Nav1.5 inactivation and contained 17 sweeps with 
an intersweep interval of 8 s. After the 100-ms prepulse to −130 
mV, the cell was clamped for 500 ms to a voltage between −135 
and −55 mV, with 5-mV increments between every sweep. The 
amount of channel inactivation, induced during the 500-ms step 
was evaluated during a subsequent 50-ms step to 0 mV, a voltage 
that opens all channels. Consequently, the amplitude of the 
current elicited during this 0-mV step was a direct measurement 
of the fraction of channels that were not inactivated. Thirdly, 
an inactivation recovery protocol was applied. After inducing 
channel inactivation with a 500-ms depolarization to −10 mV, the 
cell was clamped to −130 mV for variable times ranging between 
0.5 and 50 ms. Subsequently a short −10-mV depolarization step 
was applied to determine the number of channels that recovered 
from inactivation during the brief but time variable −130-mV 
step. Intersweep interval was 8 s. Finally, a drug wash-in protocol 
was used (100 sweeps) to monitor the development of current 
inhibition. After 80 ms at −130 mV, a 40-ms depolarizing step 
to −10 mV was applied. There was no change in voltage steps 
between sweeps and sweeps were repetitively applied at 1 Hz. 
During the intersweep time, a P/-6 protocol was applied and 
represented currents are the subtracted tracings.
Data Analysis
Current-voltage relations were obtained by normalizing the peak 
INa amplitude to the cell capacitance and plotting these values 
as a function of the applied potential. Normalized conduction-
voltage curves were obtained by approximating the linear part of 
the current-voltage relation (between +80 and +50 mV) with the 
function I = Gmax*V to determine maximal conduction Gmax. 
Dividing subsequently all the data points of the current-voltage 
relation by the calculated maximum current at that voltage, using 
the estimated Gmax, yielded the normalized conduction-voltage 
(GV) relation. Voltage dependence of channel inactivation was 
obtained by normalizing the currents elicited during the 0-mV test 
pulse of the inactivation protocol and plotting them as a function 
of the prepulse potential. The normalized GV relations, which 
represented the voltage dependence of channel opening and the 
voltage dependence of inactivation, were fitted with a Boltzmann 
equation y = 1/(1+exp(-(V-V1/2)/k)). V1/2 is the potential at which 
50% of the channels are open or inactivated, and k is the slope 
factor. Time constants of channel inactivation were obtained by 
approximating the current decay upon activation with a single 
exponential equation. The drug’s inhibiting effect was quantified 
by normalizing the steady-state currents upon drug addition to the 
control values obtained in standard ECS. The remaining current 
was then plotted against the respective drug concentration resulting 
in a concentration-effect curve. All drugs were added in the 
sequential order from the lowest to the highest concentration using 
a pressurized fast switching perfusion system. Estimate IC50 values 
for lidocaine were obtained by fitting the concentration-effect curves 
with a Hill function, y = min+((max-min)/(1+(x/IC50)-Hill slope)). All 
values are plotted as the mean ± S.E.M., with n the number of cells 
analyzed. In case of hSC-CMs also the number of independent cell 
batches is indicated, thus number of cells n/#batch. Recordings 
were excluded from analysis if the voltage error, originating from 
series resistance problem, exceeded 5 or 8 mV for the experiments 
on COS-7 and hSC-CM cells, respectively. One-way ANOVA 
method for many groups was used to find statistical significance 
in drug response (amount of current inhibition) between Nav1.5 
alone, Nav1.5+β1, and hSC-CMs. P-values lower than 0.01 were 
considered to indicate statistical significance. Data were analyzed 
using pClamp10 software (Axon CNS Molecular devices) and the 
program Sigmaplot 11 (Systat software inc., Chicago, Illinois, USA).
ReSUlTS
Before evaluating the response of drugs, the biophysical 
properties of INa were characterized in hSC-CMs and compared 
to INa of COS-7 cells expressing either Nav1.5 alone (mentioned 
throughout as Nav1.5 model) or Nav1.5 with its β1-subunit 
(Nav1.5+β1 model). First, the time-course of recovery from 
channel inactivation was determined for the three models, as it 
has been reported that β1 accelerates this recovery process (Zhu 
et al., 2017). After inducing channel inactivation, the time course 
of recovery was evaluated at −130 mV (Figure 1). Comparing 
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the three models, the Nav1.5 model recovered slightly slower 
from inactivation than the Nav1.5+β1 and hSC-CM model. Time 
constants of recovery were 5.90 ± 0.02 ms, 5.06 ± 0.01 ms, and 
5.05 ± 0.03 ms for Nav1.5, Na1.5+β1, and hSC-CMs, respectively 
(n = 5 for each model). After 50 ms repolarization at −130 mV, 
INa recovery appeared almost complete in all three models. 
Therefore, we used for the other pulse protocols a conditioning 
prepulse to −130 mV longer than 50 ms in duration to recover 
the channels from inactivation.
Representative INa recordings of COS-7 cells expressing 
either Nav1.5 alone or Nav1.5+β1, and from hSC-CMs are 
shown in Figures 2A, B. Comparing the heterologous models, 
the amplitude of INa elicited by Nav1.5+β1 was approximately a 
twofold larger compared to Nav1.5 alone. The current-voltage (IV) 
plots highlighted the increased current expression of Nav1.5+β1 
compared to Nav1.5 (Figure 2C), which supports previous 
findings that β1 facilitates the membrane incorporation of Nav1.5 
(Qu et al., 1995; Makielski et al., 1996; Zhu et al., 2017). The current 
density of Nav1.5 and Nav1.5+β1 at –20 mV amounted to −119 ± 
21 pA/pF (n = 19) and −198 ± 41 pA/pF (n = 14), respectively. The 
normalized conduction-voltage (GV) relation yielded for Nav1.5 
a V1/2 of −33.5 ± 0.3 mV with a slope factor k of 6.9 ± 0.3 (n = 
20). For Nav1.5+β1, the V1/2 amounted to −36.1 ± 0.6 mV and k 
to 7.3 ± 0.5 (n = 15), indicating that β1 did not alter the voltage 
dependence of activation significantly (Figure 2D). However, the 
voltage dependence of inactivation was shifted slightly (by +6 
mV, p-value <0.001) to more depolarized potentials when β1 was 
coexpressed, displaying inactivation curves with a V1/2 of −95.8 ± 
0.3 mV (n = 18) and −89.8 ± 0.2 mV (n = 15) with a slope factor 
k of 8.2 ± 0.3 mV and 6.8 ± 0.5 mV for Nav1.5 and Nav1.5+β1, 
respectively. Similar to the activation kinetics, no differences were 
observed in the time constants of channel inactivation between 
Nav1.5 and Nav1.5+β1 (Figure 2E).
After characterizing INa in both heterologous models, the results 
were compared to the INa of hSC-CMs. In hSC-CMs, the peak INa 
density was around −30 mV and amounted to -186 ± 25 pA/pF 
(n/# batch = 15/4). It is important to note that the recordings were 
done in ECS with normal sodium concentrations (150 mM Na+ 
extracellular). Consequently, INa amplitudes were in some cells 
too large to be controlled accurately, because of the accompanying 
voltage errors, and these recordings were excluded from analysis. 
Therefore, the reported INa density is an underestimation. One 
solution could have been to reduce the extracellular [Na+] 
(Supplemental Figure 1), as has been done previously (Lin et al., 
2015; Hayano et al., 2017; Moreau et al., 2017). However, because 
the majority of the data from heterologous expression systems 
are obtained with normal physiological extracellular [Na+], we 
opted to perform the hSC-CM recordings in similar conditions. 
After constructing the IV relation of INa in hSC-CMs, the GV 
relation was created and displayed a V1/2 of −40.2 ± 0.6 mV with 
a slope factor k of 7.4 ± 0.3 (n/#batch = 15/4). Compared to the 
data from the heterologous models, the voltage dependence 
of INa activation was in hSC-CMs shifted slightly toward more 
hyperpolarized potentials by approximately −5 mV. In contrast, 
the voltage dependence of INa inactivation was for hSC-CMs 
shifted toward more depolarized potentials compared to Nav1.5 
or Nav1.5+β1 models (Figure 2D), displaying a V1/2 of −80.0 ± 
0.4 mV (n/#batch = 7/2) with a slope factor k of 9.2 ± 0.5. Taking 
the shifts in voltage dependence into account, the kinetics of 
channel inactivation were comparable in both heterologous 
models but slightly slower in hSC-CM (Figure 2E).
The effect of the vehicle (0.1% DMSO) was evaluated and found 
not to modulate INa in either of the three models (Supplemental 
Figure 2), which agrees with what has been reported (Hyun et al., 
2017). The development of drug effect was evaluated by repetitive 
application of a depolarizing voltage step (Figure 3A). For class Ia, 
the two drugs tested were quinidine and ajmaline. Normalizing 
the steady-state current after drug addition to the control current 
yielded concentration-inhibition curves. For quinidine, all three 
models displayed a similar response to the three concentrations 
tested and no differences (p-value > 0.01) were observed (Figure 3B, 
Table 1). For ajmaline, more inhibition was observed in Nav1.5 
FIgURe 1 | INa recovery from inactivation: (A) INa recovery from inactivation example traces, chosen from the Nav1.5+β1 model. Currents were elicited with the 
inactivation recovery pulse protocol as described in material and methods, with horizontal bar at the start indicating the zero current level. Depending on the amount 
of channels that have been able to recover during the repolarizing step the amplitude of current will increase. (B) Fraction of current recovered, obtained by dividing 
the amplitude of the recovered current to the maximum current level (I/IMAX), is plotted as a function of the −130-mV prepulse duration (recovery time). Values are 
mean ± S.E.M. for Nav1.5 (black, n = 5), Nav1.5+β1 (red, n = 5), and hSC-CM (blue, n/#batches = 5/1).
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compared to both other models (Figure 3C). However, the reduced 
affinity observed upon coexpression of β1 was not sufficient to be 
statistically different from the Nav1.5 model. On the other hand, 
the response in the hSC-CMs model appeared to display a small 
but significant (p-value < 0.01) decreased sensitivity to the Nav1.5 
model (Table 1). Since β1 coexpression reduced the affinity slightly, 
there was no statistical difference (p-value >0.01) in the amount of 
current inhibition between hSC-CMs and the Nav1.5+β1 model.
Flecainide was selected as a representative drug of class Ic. For 
flecainide, the response appeared stronger in Nav1.5 compared 
to Nav1.5+β1 and hSC-CMs (Figure 4B and Table 1). However, 
the noticeable reduced response of cells expressing Nav1.5+β1 
compared to cells expressing Nav1.5 was only statistically 
significant for the 10-μM concentration (Figure 4D). The lower 
sensitivity of hSC-CMs for flecainide was found to be statistically 
significant to the response in Nav1.5 (p-value <0.001) but not 
to Nav1.5+β1 (p-value >0.01). Thus, hSC-CMs displayed a 
flecainide sensitivity comparable to that of Nav1.5+β1.
While the previous drugs displayed no or rather small 
differences between the three models, the class Ib drugs lidocaine 
and phenytoin showed a more pronounced difference between 
Nav1.5 and the two other models. In our heterologous expression 
model, Nav1.5 alone displayed for lidocaine an estimated IC50 
value of 20.4 ± 4.5 µM (n = 7, Figure 5), which is comparable 
to what has been reported (Hanck et al., 2000). Coexpression 
of β1 reduced the amount of current inhibition significantly 
at all concentrations tested (Table 1). Approximating the 
concentration-effect curve of Nav1.5+β1 yielded an estimated 
IC50 value of 59 ± 6.3 µM (n = 10). Besides the shift toward higher 
lidocaine concentrations, the maximal amount of inhibition 
was reduced from approximately 80% in Nav1.5 to 60% in 
Nav1.5+β1 (Figure 5B). Interestingly, the effect of lidocaine on 
INa of hSC-CMs was more similar to Nav1.5+β1 than to Nav1.5 
alone. Likewise, the amount of current inhibition was at all 
concentrations significantly lower in hSC-CMs compared to 
Nav1.5 alone. In contrast, no significant difference in amount of 
INa inhibition was observed between hSC-CMs and Nav1.5+β1 
(Table 1). hSC-CMs displayed an estimated IC50 of 116 ± 5 µM 
with a maximal inhibition of approximately 60% (n/#batch = 
11/2). In neither of the models did lidocaine alter the kinetics of 
INa activation and inactivation (Supplemental Table 1).
Phenytoin was selected as second member of the Ib class of 
drugs. The response observed in the Nav1.5 model was in line 
with what has been reported, yielding an estimated IC50 of 30 ± 14 
µM (Sanchez-Chapula and Josephson, 1983; Xu et al., 1991). 
Similar to what was observed for lidocaine, both Nav1.5+β1 
and hSC-CM models displayed a significant reduced sensitivity 
to phenytoin compared to Nav1.5 alone (Figure 6 and Table 1). 
FIgURe 2 | Activation and inactivation of INa: (A) Representative INa recordings elicited with the activation pulse protocol (shown below) for Nav1.5, Nav1.5+β1, and 
hSC-CM. Zero current level is indicated by horizontal bar at the start. (B) INa recordings to determine the voltage-dependence of channel inactivation elicited with 
the inactivation pulse protocol (shown below). (C) IV curves obtained from analyzing current recordings shown in panel (A). The peak INa currents were normalized 
to the cell capacitance and plotted as a function of applied potential. Shown values are mean ± SEM for Nav1.5 (black, n = 20), Nav1.5 + β1 (red, n = 15), and 
hSC-CM INa (blue, n/#batch = 17/4). (D) Voltage dependence of inactivation obtained from analyzing current recordings shown in panel B. Note, coassembly of 
Nav1.5 with β1 (red circles, n = 15) shifted the voltage dependence of inactivation toward more depolarized potentials compared to Nav1.5 alone (black circles, n = 
17). INa of hSC-CM (blue circles, n/#batch = 7/2) inactivated at more depolarized potentials compared to Nav1.5 and Nav1.5+β1. The average voltage dependence 
of activation, obtained from analyzing the IV curves of panel C, are represented with solid lines. (e) Plot displays the time constants of inactivation, which were 
obtained by approximating the current decay from recordings shown in panel A with a single exponential function. No marked differences were observed between 
Nav1.5 alone (black, n = 12), Nav1.5+β1 (red, n = 14), and INa in hSC-CMs (blue, n/#batch = 10/2).
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At the highest concentration of 300 µM phenytoin tested, Nav1.5 
displayed approximately 70% of current inhibition whereas in 
both Nav1.5+β1 and hSC-CM it did not yield more than 50%. 
Kinetics of activation and inactivation did not seem affected 
by phenytoin (Supplemental Table 1). However, it has been 
reported that INa inhibition by phenytoin depends on the potential 
of the conditioning prepulse due to a higher affinity of the drug 
for the inactivated state (Sanchez-Chapula and Josephson, 1983). 
Hereto, the development of current inhibition was re-evaluated 
using a more positive prepulse potential, e.g., −90 mV instead 
of −130 mV, to promote channel inactivation. As a potential 
of  −90 mV was sufficient to induce channel inactivation, only 
a fraction (between 10% and 30%, Figure 2D) of the channels 
was available and the current activation elicited was already 
in control conditions less than using a prepulse of −130 mV. 
Nevertheless, the current amplitudes were sufficient to determine 
the amount of current inhibition for hSC-CM and Nav1.5+β1. 
Concentration-effect curves indicated that the amount of current 
inhibition was indeed increased with a prepulse potential of −90 
mV compared to −130 mV. Since Nav1.5 alone displayed a more 
hyperpolarized voltage dependence of inactivation compared to 
both other models (Figure 2D), we decided to take this shift into 
account and used a −100-mV prepulse instead. Furthermore, 
with a prepulse of −90 mV, the noninactivated fraction of INa in 
Nav1.5 became insufficient in amplitude to determine channel 
inhibition accurately. Although the difference in INa inhibition of 
hSC-CMs and Nav1.5+β1 compared to Nav1.5 was smaller with 
more depolarized prepulse potentials (Figure 6 and Table 1), the 
sensitivity of Nav1.5 remained a twofold higher and significantly 
different from both other models (p-value <0.01). The response of 
hSC-CM and Nav1.5+β1 was also with a more depolarized −90-
mV prepulse similar and did not differ significantly from 
each other.
DISCUSSION
The aim of this study was i) to determine the contribution of β1 in 
the pharmacological responses to different classes of INa blockers 
and ii) to compare the affinity of known INa inhibitors between 
Nav1.5 +/− β1 expressed in heterologous cell lines and hSC-CMs 
(Cor.4U cardiomyocytes), cells now used extensively in high-
throughput system safety derisking testing (Nozaki et al., 2014; 
Maddah et al., 2015; Zeng et al., 2016; Kopljar et al., 2018). In our 
study, using COS-7 cells, the INa density increased, as expected, 
in the presence of β1. The modulation of channel kinetics by β1 
appeared to be minor but reported effects by others have been 
known to be variable (Isom et al., 1995; Makielski et al., 1996; Dhar 
Malhotra et al., 2001; Watanabe et al., 2008; Zhu et al., 2017). This 
FIgURe 3 | Quinidine and ajmaline INa drug response: (A) From left to right representative steady-state INa recordings of Nav1.5, Nav1.5+β1 and hSC-CM upon 
application of different ajmaline concentrations. Represented conditions are the current amplitudes in absence of drug (control condition, black trace), 3 (red), 
10 (blue), and 30 µM (grey) ajmaline, respectively. Currents were elicited by repetitively pulsing to −10 mV as described in material and methods. Starting from 
the lowest to the highest concentration, every concentration was washed-in until a steady-state effect on the current was observed. Horizontal bar at the start 
represents the zero current level. (B, C) Concentration-effect curves obtained by plotting the normalized current (I/IMAX) as a function of applied quinidine (panel B) 
and ajmaline (panel C) concentration, respectively. For each drug the response of the three different models is shown; Nav1.5 (black circles, quinidine n = 8, ajmaline 
n = 6), Nav1.5+β1 (red circles, quinidine n = 7, ajmaline n = 7), and hSC-CMs (blue circles, quinidine n/#batch = 12/3, ajmaline n/#batch = 8/1).
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variation may relate to differences in experimental setup such as the 
type of cells used (Moran et al., 2003). For the voltage dependence 
of activation and its kinetics we observed no marked differences 
between Nav1.5 and Nav1.5+β1, as has been reported (Makielski 
et al., 1996; Dhar Malhotra et al., 2001; Zhu et al., 2017). The voltage 
dependence of inactivation displayed, in the presence of β1, a small 
shift of approximately +6 mV toward more depolarized potentials 
without affecting the kinetics of inactivation. In literature, a similar 
shift in depolarization has been reported that varies between 5 (Dhar 
Malhotra et al., 2001) and 12 mV (Zhu et al., 2017). Recovery of 
inactivation was slightly accelerated with β1, as reported (Watanabe 
et al., 2008; Zhu et al., 2017).
The INa was well expressed in the hSC-CMs used, and the 
current amplitudes obtained were in line with what has been 
reported (Moreau et al., 2017). Voltage dependence of activation 
displayed a −10 mV shift to more hyperpolarized potentials 
compared to our heterologous Nav1.5 and Nav1.5+β1 models 
(Figure 2D) (Valdivia et al., 2002). On the other hand, the voltage 
TABle 1 | Amount of current inhibition per drug concentration is represented for each model as mean % block ± S.E.M. % block per drug concentration was 
statistically evaluated to obtain p-values for differences in response between the models: Nav1.5+β1 vs. Nav1.5, hSC-CM vs. Nav1.5, and hSC-CM vs. Nav1.5+β1, 
respectively. 
Drug µM p-value
Nav1.5 Nav1.5+β1 hSC-CM Nav1.5+β1  hSC-CM hSC-CM
% block % block % block Nav1.5 Nav1.5 Nav1.5+β1 
Ia Quinidine 3 14 ± 3 14 ± 3 11 ± 2 not significant (0.266)
10 35 ± 3 31 ± 3 28 ± 2 not significant (0.114)
30 65 ± 1 59 ± 5 65 ± 3 not significant (0.388)
Ajmaline 3 18 ± 2 21 ± 3 17 ± 3 not significant (0.564)
10 67 ± 4 57 ± 3 47 ± 2 0.044 <0.001 0.055
30 88 ± 2 81 ± 3 72 ± 2 0.029 <0.001 0.083
Ib Lidocaine 3 20 ± 2 7 ± 1 7 ± 1 <0.001 <0.001 0.807
10 31 ± 3 19 ± 2 12 ± 1 <0.001 <0.001 0.003
30 56 ± 2 37 ± 2 26 ± 2 <0.001 <0.001 <0.001
100 69 ± 1 56 ± 3 43 ± 3 0.009 <0.001 0.005
300 87 ± 2 69 ± 3 52 ± 3 <0.001 <0.001 <0.001
1000 89 ± 2 74 ± 3 72 ± 2 0.001 <0.001 0.531
Phenytoin 3 11 ± 1 3 ± 1 4 ± 1 <0.001 <0.001 0.362
10 17 ± 2 11 ± 2 6 ± 1 0.027 <0.001 0.027
30 40 ± 2 21 ± 2 17 ± 1 <0.001 <0.001 0.150
100 59 ± 2 36 ± 4 33 ± 2 <0.001 <0.001 0.449
300 70 ± 2 48 ± 1 45 ± 3 <0.001 <0.001 0.071
Phenythoin 3 27 ± 3 16 ± 5 11 ± 2 0.03 <0.001 0.195
depolarised 10 50 ± 2 38 ± 5 39 ± 4 not significant (0.209)
Pre-pulse 100 76 ± 2 58 ± 5 58 ± 2 0.002 0.002 0.934
Ic Flecainide 3 33 ± 3 28 ± 3 25 ± 2 not significant (0.058)
10 73 ± 2 61 ± 3 54 ± 2 0.001 <0.001 0.031
30 89 ± 1 89 ± 1 83 ±2 not significant (0.012)
Significance of difference is achieved if the value was <0.01. Not significant indicates that no significant difference between models was obtained with the p-value between parentheses.
FIgURe 4 | Flecainide INa drug response (A) From left to right representative steady-state INa recordings of Nav1.5, Nav1.5+β1 and hSC-CM elicited at −10 mV 
depolarization and presence of different flecainide concentrations. Represented conditions are the current amplitudes in absence of drug (control, black trace), 
3 (red), 10 (blue), and 30 µM (grey) flecainide, respectively. Horizontal bar indicates zero current level. (B) Concentration-effect curves obtained by plotting the 
normalized current (I/IMAX) as a function of applied flecainide concentration. The drug response of the three different models are displayed, Nav1.5 (black, n = 16), 
Nav1.5+β1 (red, n = 14), and hSC-CMs (blue, n/#batch = 15/3).
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dependence of inactivation was in hSC-CM shifted by 5 to 10 mV 
toward more depolarized potentials compared to Nav1.5+β1 or 
Nav1.5, respectively (Figure 2D). While the rate of inactivation 
did not show differences, the recovery process was slightly 
accelerated in hSC-CMs compared to Nav1.5 alone resembling 
the condition when both Nav1.5 and β1 are expressed. Thus, INa 
of hSC-CM resembled most to the INa generated in COS-7 cells 
expressing both Nav1.5+β1. Although the electrophysiological 
properties suggest that the INa in hSC-CMs is largely mediated 
by β1, it has to be taken into account that the β1 subunit is 
most likely not the only auxiliary subunit and other modulating 
processes can influence the kinetics of INa in hSC-CMs.
In order to use hSC-CM in safety pharmacology studies, it is 
important to know the effect of coexpressing β1 with Nav1.5 on 
FIgURe 6 | Phenytoin INa drug response (A) Representative current recordings from Nav1.5 (left), Nav1.5+β1 (middle), and hSC-CM (right) upon application of different 
phenytoin concentrations. Steady-state current amplitudes are shown for control condition (black), 10 (red), 30 (blue), and 100 µM phenytoin (grey), respectively. Zero 
current level is indicated by the horizontal bar at the start. (B) Representative current recordings from hSC-CM upon application of different phenytoin concentrations and 
with a more depolarized prepulse to −90 mV. Steady-state current amplitudes are shown for control condition (black), 10 (red), 30 (blue), and 100 µM phenytoin (grey), 
respectively. (C) The normalized current (I/IMAX) as a function of applied phenytoin concentration for Nav1.5 (black circle, n = 10), Nav1.5+β1 (red circle, n = 10), and hSC-
CMs (blue circle, n/#batch = 12/3). (D) Concentration-effect curves obtained with a more depolarized prepulse (−100 mV for Nav1.5 and −90 mV for Nav1.5+β1 and 
hSC-CMs) are represented for Nav1.5 (black triangle, n = 5), Nav1.5+β1 (red triangle, n = 5), and hSC-CMs (blue triangle, n/#batch = 8/2). (e) Concentration-effect curves 
obtained for hSC-CMs at prepulse potentials of −130 (blue circle, retaken from panel C) or −90 mV (blue triangle, retaken from panel D).
FIgURe 5 | Lidocaine INa drug response (A) From left to right representative steady-state INa recordings of Nav1.5 (left), Nav1.5+β1 (middle), and hSC-CM (right) 
upon application of different lidocaine concentrations. Represented conditions are the current amplitudes in absence of drug (control, black trace), 10 (red), 30 
(blue), and 100 µM (grey) lidocaine, respectively. Zero current level is indicated by the horizontal bar at the start. (B) The response (I/IMAX) to applied lidocaine 
concentration is shown for the three different models, Nav1.5 (black, n = 7), Nav1.5+β1 (red, n = 10), and hSC-CM (blue, n/#batch = 11/2). Note the difference in 
the response to lidocaine between Nav1.5 alone and in presence of β1.
Frontiers in Pharmacology | www.frontiersin.org December 2015 | Volume 10 | Article 1374
INa in hSC-CMs Is Composed of Nav1.5+β1Van de Sande et al.
9
the latter’s response to drugs. Quinidine (class Ia) inhibits Nav1.5 
with a reported IC50 of 9.7 µM (Snyders et al., 1992; Harmer et al., 
2011). Our results are in agreement and no difference in quinidine 
sensitivity was observed between the three models (Figure 3 and 
Table 1). Ajmaline (class Ia) has a reported IC50 of approximately 
27.8 µM, measured in rat ventricular cardiomyocytes (Bébarová 
et al., 2005). Using heterologously expressed INa in COS-7 cells, we 
observed slightly higher affinities as 10 μM inhibited more than 
50% of the INa (Table 1). However, no significant differences were 
observed between Nav1.5 and Nav1.5+β1. hSC-CMs displayed 
a slightly reduced ajmaline sensitivity compared to Nav1.5 
alone, with a difference of less than a twofold it comes close to 
the reported affinity in rat ventricular myocytes. Compared to 
Nav1.5+β1 the ajmaline response was in hSC-CMs similar.
Flecainide (class Ic) has a reported IC50 between 6 and 7 µM 
(Nitta et al., 1992; Ramos and Leary, 2004), which is comparable to 
our findings. Similar to the class Ia drugs, there was only a minor 
(not significant) difference in the response upon coexpression 
of β1 compared to Nav1.5 alone. Thus, likewise to the evaluated 
class Ia compounds, β1 did not affect flecainide affinity. When 
comparing the effect of flecainide in hSC-CMs to that of the 
heterologous models, hSC-CMs displayed a small but significant 
lower affinity compared to Nav1.5 at the 10-μM concentration. 
Compared to Nav1.5+β1 the response was similar in hSC-CMs 
(Table 1). Collectively, the data show that the responses of 
Nav1.5 to class Ia and Ic drugs is not markedly affected by β1 and 
the sensitivity of heterologous expression models and hSC-CMs 
is comparable.
On the other hand, the affinity of Nav1.5 for the class Ib drugs 
lidocaine and phenytoin was significantly decreased upon β1 
expression. Lidocaine is a use-dependent inhibitor with a reported 
IC50 of 45 µM for the Nav1.5 channel (Bean et al., 1983; Bennett 
et al., 1995). We observed a similar response for Nav1.5 alone 
but the obtained inhibition was in both Nav1.5+β1 and hSC-
CMs about a twofold to threefold lower (Figure 5 and Table 1). 
A previous study using Xenopus Laevis oocytes as expression 
model, reported a similar finding and coexpression of β1 reduced 
Nav1.5’s lidocaine sensitivity (Makielski et al., 1996). To compare 
the lidocaine response of our three models to what is reported for 
native human myocytes, we need to consider that lidocaine is a 
use-dependent blocker and the pulse frequency will substantially 
determine the amount of INa block. Using a similar pulse protocol, 
evaluating INa inhibition at 1−2 Hz pulsing, 200 μM lidocaine 
gave between 20% and 35% of INa inhibition in human myocytes 
(Jia et al., 1993; Furukawa et al., 1995). In our conditions, 
heterologous expression of only Nav1.5 displays more than 80% 
inhibition whereas coexpression of β1 reduces it to approximately 
65% (Figure 5). hSC-CMs displayed an even lower sensitivity, 
although not significant different from the Nav1.5+β1, and 200 
μM lidocaine would inhibit around 55% of the INa (determined at 
1 Hz pulsing, Figure 5). Thus, the lidocaine response of INa in hSC-
CMs compares best to the reported effect in human myocytes but 
the affinity in hSC-CMs appears slightly higher.
Evaluating the inhibitory effect of phenytoin, a similar picture 
emerged and COS-7 cells coexpressing Nav1.5+β1 displayed a 
lower affinity than Nav1.5 alone. The hSC-CM model resembled 
the response of Nav1.5+β1 and both displayed a significant 
lower sensitivity compared to Nav1.5 (Table 1), which showed 
an affinity similar to what has been reported (Ragsdale et al., 
1991). When the conditioning prepulse, used to recover INa 
inactivation, was more depolarized (i.e., from −130 to −90 
mV for Nav1.5+β1 and hSC-CM or −100 mV for Nav1.5), the 
sensitivity to phenytoin and amount of INa inhibition increased. 
The increased sensitivity with a more depolarized voltage, or a 
more depolarized resting membrane potential, is explained by 
the observation that phenytoin is an inactivated state blocker, i.e., 
when channel inactivation is promoted, also channel inhibition 
is increased. Most likely, a similar finding can be predicted for 
lidocaine as this drug is also reported to bind the channel when it 
is inactivated (Lu et al., 2010).
Analyzing the pharmacological response of INa, the hSC-CM 
model resembled best the heterologous Nav1.5+β1 model, 
supporting the fact that β1 forms part of the auxiliary subunits 
modulating the Nav1.5 channel in hSC-CM (Moreau et al., 
2017). The β1 subunit modulates the inactivation kinetics of 
the Nav1.5 channel and, by doing so, it affects the sensitivity 
to drugs that bind the inactivated state, such as lidocaine 
and phenytoin. However, even when we compensated for 
the observed shift in voltage dependence of inactivation and 
compared the response with a prepulses to −100 mV for Nav1.5 
and a prepulse to −90 mV for Nav1.5+β1 and hSC-CMs, a small 
significant difference remained between Nav1.5 and the other 
two models. This indicated that, besides the indirect effect of 
β1 on drug response by modulating the inactivation kinetics, 
β1 affects phenytoin sensitivity directly. A similar finding has 
been reported for lidocaine, whereby β1 reduces the sensitivity 
(Makielski et al., 1996).
Interestingly, Nav1.5’s affinity to mexiletine, a class Ib drug 
that shows structural similarity with lidocaine, has been shown 
to be affected by mutations that alter the activation of the voltage 
sensor of domain III (DIII-VSD) (Zhu et al., 2018). Structural 
data shows that the transmembrane helix of β1 is indeed in the 
vicinity of DIII-VSD (Yan et al., 2017; Pan et al., 2018), which hints 
toward a mechanism whereby β1 lowers lidocaine and phenytoin 
affinity by affecting DIII-VSD. Alternatively, because β1 binds 
with its extracellular part to the S5-S6 transmembrane segments 
of Domain I and IV (Makita et al., 1996), this interaction leads to 
conformational changes in the binding site(s) for both lidocaine 
and phenytoin that involves the S6 of Domain IV (Pless et al., 
2011; Tikhonov and Zhorov, 2017; Nguyen et al., 2019).
In several cases, drug binding requires a specific channel 
conformation, e.g., the channel’s inactivated state. The occupation 
of certain states is dependent on the interpulse holding potential 
or in case of hSC-CM the resting membrane potential (RMP). 
As it is reported that the RMP of hSC-CMs is variable (Ma et al., 
2011; Davis et al., 2012; Doss et al., 2012; Liang et al., 2016; 
Vaidyanathan et al., 2016; Chen et al., 2017; Hayano et al., 2017), 
this RMP variability needs to be considered when evaluating 
drug responses using techniques that do not control the RMP, 
which agrees with the observation that INa drug response is best 
determined under voltage-clamp condition (Goodrow et al., 
2018). For open channel blockers, like some class Ia and Ic drugs, 
a more depolarized RMP means more channels are inactivated 
and the drug will not be able to block the channel. On the other 
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hand, blockers with a high affinity for the inactivated state will 
exert a more pronounced effect. A recent study showed that 
phenytoin at 5 µM (i.e., a therapeutic concentration, used as 
anticonvulsant, not associated with cardiovascular effects in the 
clinic), sometimes affected the spontaneous beating of hSC-CMs 
causing in some experiments up to 50% beating arrest of the 
monolayer (Kopljar et al., 2018). These effects might originate 
from variability in RMP between different hSC-CM cultures, 
hereby affecting the amount of INa being blocked by phenytoin. In 
our setup, using voltage clamp, the interpulse holding potential 
was well controlled allowing for accurate assessment of the 
pharmacological response.
Overall, our data indicate that the pharmacological response 
for the five drugs evaluated on INa in hSC-CMs compares better to 
the response in heterologous expressed Nav1.5+β1 currents than 
currents composed of Nav1.5 alone. However, β1 is not the only 
interacting subunit and other auxiliary subunits of Nav1.5 (other 
β subunits and scaffolding proteins) are probably expressed in 
hSC-CM (Abriel, 2010). Furthermore, even other channels, such 
as the Kir2.1 K+ channel, can form complexes with Nav1.5 (Willis 
et al., 2015; Utrilla et al., 2017; Ponce-Balbuena et al., 2018). As 
these subunits and interactions can modulate the response of 
Nav1.5, the expression of them in hSC-CMs most likely explains 
the observed difference in INa kinetics between hSC-CMs and 
heterologous expressed Nav1.5+β1 (Figure 1). Furthermore, 
although Nav1.5 is the main α-subunit of the INa in hSC-CM, 
most likely other Nav channel subunits contribute to the total 
INa expressed (Moreau et al., 2017). For completeness, all these 
factors should be taken into account and the observed difference 
in drug response between hSC-CM and heterologous expressed 
Nav1.5 cannot be ascribed to β1 alone. Anyway, our data shows 
that i) the β1-subunit influences the affinity for class Ib drugs but 
not for the class Ia and Ic compounds evaluated and ii) the drug 
response of INa in hSC-CMs compares very well to INa of COS-7 
cells expressing Nav1.5+β1.
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